Pull to refresh
Logo
What Changed
Following Why Sign Up
Lilly's oral GLP-1 Foundayo clears cardiovascular safety bar in largest type 2 diabetes trial

Lilly's oral GLP-1 Foundayo clears cardiovascular safety bar in largest type 2 diabetes trial

New Capabilities

EU regulator backs Foundayo for obesity and type 2 diabetes as the FDA weighs the US diabetes decision

October 16th, 2026: EMA panel recommends EU approval of Foundayo for obesity and type 2 diabetes

Overview

Updated Oct 18

Millions with type 2 diabetes manage blood sugar with daily injections. Lilly's Foundayo is a pill that could replace them, and in its largest trial it matched insulin on heart safety while cutting weight and blood sugar more.

The FDA approved Foundayo for obesity in April; a type 2 diabetes decision is still pending. On October 16, the European Medicines Agency's expert panel recommended EU approval for both weight management and type 2 diabetes. Foundayo is a once-daily pill that mimics the gut hormone GLP-1, with no fasting rules, unlike Novo Nordisk's Rybelsus.

Why it matters

If approved, an oral GLP-1 with no fasting rules could replace daily injections for millions, pressuring Novo Nordisk's semaglutide franchise.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

16%
Lower risk of MACE-4 events vs insulin glargine
Heart attack, stroke, cardiovascular death, or hospitalization for unstable chest pain (hazard ratio 0.84).
57%
Lower risk of all-cause death vs insulin glargine
Pre-planned analysis; not controlled for multiplicity (nominal p = 0.002).
April 1, 2026
FDA approval for obesity
Orforglipron cleared for chronic weight management; the type 2 diabetes decision is still pending.
Oct 16, 2026
EU panel recommends approval
CHMP backed Foundayo for both obesity and type 2 diabetes; the European Commission typically follows within weeks.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

RB
Rachel Batterham
Senior vice president of medical innovation and external engagement, Lilly Cardiometabolic Health
Active

Organizations Involved

Eli Lilly and Company
Eli Lilly and Company
Pharmaceutical company
Developer of Foundayo (orforglipron); FDA approved the drug for obesity in April 2026; CHMP recommended EU approval for obesity and type 2 diabetes on October 16, 2026; type 2 diabetes FDA submission planned for end of Q2 2026

Indianapolis-based drugmaker developing Foundayo, an oral GLP-1 receptor agonist.
Novo Nordisk
Novo Nordisk
Pharmaceutical company
Main rival; markets oral semaglutide (Rybelsus) and injectable semaglutide (Ozempic, Wegovy)

Danish drugmaker whose oral semaglutide is currently the only oral GLP-1 on the market.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulator
Approved orforglipron (Foundayo) for obesity in April 2026; reviewing the type 2 diabetes application

US regulator responsible for approving new drugs and reviewing clinical trial data.

Timeline

April 2026 October 2026

5 events Latest: October 16th, 2026 · 4 weeks ago
Tap a bar to jump to that date

  1. EMA panel recommends EU approval of Foundayo for obesity and type 2 diabetes

    Latest Regulatory

    The European Medicines Agency's CHMP recommended marketing authorization for both indications. The European Commission typically follows within weeks; approval would make Foundayo the second oral GLP-1 for weight management in the EU, after Novo's Wegovy pill.

  2. Full ACHIEVE-4 results reaffirm safety and sustained metabolic gains

    Trial Results

    Lilly detailed 16% lower MACE-4 risk and 53% lower cardiovascular death risk, with A1C and weight benefits persisting through 104 weeks.

  3. EASD indirect comparison favors Foundayo over oral semaglutide 25 mg

    Conference Presentation

    Analysis of ACHIEVE-3 and PIONEER PLUS data showed greater A1C and weight reduction for Foundayo 17.2 mg at 52 weeks.

  4. ACHIEVE-4 topline shows non-inferior heart risk, 57% lower death

    Trial Results

    Lilly reported orforglipron matched insulin glargine on heart safety and beat it on A1C and weight; FDA submission planned by end of Q2.

  5. FDA approves Foundayo for obesity

    Regulatory

    The FDA cleared orforglipron for chronic weight management. Its approval letter asked Lilly for more data on heart risk, liver injury, delayed stomach emptying, and effects in lactating women.

Scenarios

1

FDA approves Foundayo for type 2 diabetes

Likely Resolves by Q2 2027

Discussed by: Lilly company statements; analysts covering the diabetes market

Lilly said it planned to file by the end of Q2 2026 under a Priority Review Voucher. If the FDA accepts the application with priority review, a decision could land within roughly six to ten months. Approval would make orforglipron the first small-molecule oral GLP-1 with no fasting requirement.

2

FDA approval for obesity extends Foundayo beyond diabetes

Possible Resolves by Q2 2028

Discussed by: Lilly's ATTAIN program; obesity market analysts

Lilly is running the ATTAIN program studying orforglipron for chronic weight management. Success would put the pill into the broader obesity market, where oral dosing could draw patients who avoid injectable weight-loss drugs. The timeline for a filing and decision would follow the diabetes approval.

3

Foundayo overtakes oral semaglutide in US prescriptions

Possible Resolves by End of 2028

Discussed by: Market analysts; EASD indirect comparison data

Indirect comparisons show Foundayo 17.2 mg delivers more A1C reduction and weight loss than oral semaglutide 25 mg, with no fasting rules. If approved, prescription share will reveal whether the pill becomes the standard oral GLP-1 or whether Novo's brand loyalty holds.

4

European Commission approves Foundayo for obesity and type 2 diabetes

Likely Resolves by Nov 30, 2026

Discussed by: European Medicines Agency CHMP; Lilly's international regulatory strategy

The CHMP recommended marketing authorization on October 16. The European Commission usually follows the advice within weeks. Approval would make Foundayo the second oral GLP-1 for weight management in the EU, after Novo's Wegovy pill, and a rival to Rybelsus for diabetes.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

September 2019

Rybelsus oral semaglutide launch (2019)

The FDA approved Rybelsus, the first oral GLP-1 drug, for type 2 diabetes. Patients had to fast 30 minutes before and after each dose and take it on an empty stomach, which limited convenience.

Then

Rybelsus sold far below Novo's injectable Ozempic, whose once-weekly dosing dominated.

Now

It proved an oral GLP-1 could work, setting the stage for small-molecule versions without the fasting burden.

Why this matters now

Orforglipron targets the same mechanism but removes the fasting requirement and shows stronger results in indirect comparisons, attacking the exact weakness that held Rybelsus back.

2017-2021

Semaglutide becomes a blockbuster (2017-2021)

Novo Nordisk's injectable semaglutide, sold as Ozempic for diabetes and Wegovy for obesity, turned GLP-1 drugs into the best-selling medicine class in the world.

Then

Demand for weight-loss drugs outstripped supply and drove Novo's valuation past most European companies.

Now

The category's scale drew Lilly and others into a fierce race for the next generation of oral options.

Why this matters now

The blockbuster market shows what an oral competitor stands to capture and why Lilly pushed orforglipron through a huge cardiovascular trial before filing.

Sources

(11)
+5
Eli Lilly and Company PR Newswire Eli Lilly Investor Relations Healio / Endocrine Today Drugs.com MedNews Nova Pharma News Cardiac Vascular News Fierce Pharma Reuters Pharmaceutical Executive PR Newswire